| Filed On | Filing |
|---|---|
| 23 Oct 2026 |
8-K: Other Events
Disclaimer Aardvark Therapeutics, Inc. (“we”, “us,” “our” or the “Company”) does not (nor its respective affiliates, directors, members, officers, employees or agents) make any representation or warranty, express or implied, as to, and n... |
| 22 Oct 2026 |
8-K: Other Events
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data |
| 08 Oct 2026 |
Form 4: Zhang Zhongwei, Director
Granted 127,061 Stock Option (right to buy) |
| 08 Oct 2026 |
Form 3: Zhang Zhongwei, Director
No securities owned |
| 08 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Other Events
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 |
Form 4: Sun Nelson, See Remarks
Sold 14,754 shares ($73.8K) · Sold 62,000 shares ($321K) |
| 10 Sep 2026 | 144 |
| 21 Aug 2026 |
Form 4: Chi Jeffrey, Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Graf Susan E, Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Baynes Roy D., Director
Granted 44,964 Stock Option (right to buy) |
| 21 Aug 2026 |
Form 4: Tong Victor Edward Jr, Director
Granted 44,964 Stock Option (right to buy) |
| 17 Aug 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 10 Jul 2026 | ARS |
| 10 Jul 2026 | Proxy statement: annual meeting on August 14, 2026 |
| 29 Jun 2026 | PRE 14A |
| 12 Jun 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 14 May 2026 | 8-K: Other Events |
Loading...
